Ghe LLC Buys 52,392 Shares of Abbott Laboratories $ABT

Ghe LLC increased its position in shares of Abbott Laboratories (NYSE:ABT) by 390.1% during the first quarter, Holdings Channel reports. The institutional investor owned 65,824 shares of the healthcare product maker’s stock after purchasing an additional 52,392 shares during the quarter. Abbott Laboratories comprises 1.4% of Ghe LLC’s holdings, making the stock its 12th biggest position. Ghe LLC’s holdings in Abbott Laboratories were worth $6,758,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter valued at $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories during the 4th quarter worth $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.0%

Shares of ABT stock opened at $93.97 on Monday. The firm’s fifty day moving average price is $89.21 and its two-hundred day moving average price is $103.09. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $163.69 billion, a P/E ratio of 26.32, a PEG ratio of 1.62 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the previous year, the business earned $1.09 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on ABT shares. Stifel Nicolaus cut their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Sanford C. Bernstein dropped their price target on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Oppenheimer reduced their price objective on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, Piper Sandler reiterated an “overweight” rating and set a $115.00 price objective on shares of Abbott Laboratories in a report on Monday, June 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $118.42.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.